Please assess the completion status of the following clinical trial:

Trial Title: Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Male and/or female participant, between 18 and 55 years of age, inclusive. Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 30.0 kg/m2, inclusive.~Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).~Having given written informed consent prior to undertaking any study-related procedure.~Not under any administrative or legal supervision or under institutionalization due to regulatory or juridical order.~Exclusion Criteria:~Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteo-muscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.~Personal medical history of seizure.~Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).~Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, with the exception of hormonal contraception or menopausal hormone replacement therapy; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion.~Positive result for hepatitis B, C or HIV~Positive result on urine drug screen~Positive alcohol test.~Any consumption of citrus fruits or their juices within 5 days before inclusion.~Current psychiatric disorder, suicidal ideation in the previous 6 months (as assessed by the C-SSRS), or a lifetime suicide attempt.~Additional exclusion criteria applied, and specially for Part 1b, criteria related to the study procedure of lumbar puncture.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- SAR443820 (Type: EXPERIMENTAL): Single dose oral ascending dose (parts 1a and 1b) and multiple ascending oral dose (part 2) of SAR443820
- Placebo (Type: PLACEBO_COMPARATOR): Single dose oral ascending dose (part 1a) and multiple ascending oral dose (part 2) of matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).